Podcasts about BCG

In this week's MBA Admissions podcast we began by discussing the current state of the MBA admissions season. We are now getting close to the end of the interview invite season for Round 2 as top MBA programs begin to release their final decisions. This upcoming week, UNC / Kenan Flagler, Duke / Fuqua, Michigan / Ross, Notre Dame / Mendoza, SMU / Cox and Imperial Business School are releasing their Round 2 decisions. A few MBA programs are also beginning their next admissions rounds, including Georgia / Terry, IESE and Maryland / Smith. Graham highlighted upcoming MBA webinar events. On March 19, we are hosting a series of panel discussions focused on international students who are targeting the top MBA programs in the United States. On May 11, Clear Admit is hosting our in-person MBA Fair in Atlanta. Signups for these events are here: https://www.clearadmit.com/events Graham then highlighted several MBA admissions tips, focusing on Welcome Weekend events, the importance of pre-MBA coursework for MBA applicants, and two that focus on deferred admissions at UPenn / Wharton and Columbia. Finally, Graham addressed the new season of Real Humans Alumni. This week focuses on four alumni from Rice / Jones at Bain, NYU / Stern at BCG, Harvard at Amazon and CMU / Tepper at Morgan Stanley. For this week, for the candidate profile review portion of the show, Alex selected two ApplyWire entries and one DecisionWire entry: This week's first MBA admissions candidate is from India and is looking to pivot from accounting to finance. They are applying next season and still need to take the GMAT exam. This week's second MBA applicant has a 316 GRE score and is planning to retake the GRE before applying next season. We believe they will have a really strong profile if they can raise their GRE score. This week's final MBA candidate is deciding between Fuqua, Goizueta and Owen. This episode was recorded in Paris, France and Cornwall, England. It was produced and engineered by the fabulous Dennis Crowley in Philadelphia, USA. Thanks to all of you who've been joining us and please remember to rate and review this show wherever you listen!

In this podcast, experts Ashish M. Kamat, MD, MBBS, Katie S. Murray, DO, MS, and Thomas Powles, MD, MBBS, MRCP, discuss the classification of BCG responsiveness and intravesical and systemic therapies for non-muscle invasive bladder cancer.

Rethinking Compliance Across Asia with Barbara TsaiCompliance in Asia is no longer just about applying a Western-designed playbook to a different region with a completely different regulatory environment. It requires understanding how enforcement, politics, and business realities intersect in markets that expect global companies to follow local rules on local terms.In this episode our host Hanjo Seibert welcomes Barbara Tsai, a compliance leader at Microsoft, based in Asia with experience spanning public sector work, private practice as well as a major Swiss financial institution.As part of our Innovation series, Barbara and Hanjo look at what's changing in compliance across Asia and also touch on how AI can turn compliance into a true source of innovation.On BCG on Compliance, we dive deep into the extraordinary minds that are driving that change.From crime prevention gurus to ethics champions, we'll ask provocative questions and bring you rich insights from the global players shaping the future of compliance, all in a dynamic and compact 20-minute episode.Whether you're a seasoned pro or new to the field, BCG on Compliance is your quick, comprehensive guide. Join us as we explore the profound ways compliance is altering industries around the globe. And connect with us at bcgoncompliance@bcg.comNew episodes are released monthly.Listen wherever you get your podcasts.Episode LinksHanjo Seibert LinkedInBarbara TsaiBCG WebsiteBCG LinkedInApple: https://podcasts.apple.com/ca/podcast/bcg-on-compliance/id1716794444

Dr. Monty Pal and Dr. Andrea Apolo discuss practice-changing studies and other novel approaches in bladder, kidney, and prostate cancers that were presented at the 2026 ASCO Genitourinary Cancers Symposium. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles.  And today is super exciting, we're highlighting key abstracts that were presented at the 2026 ASCO GU Cancers Symposium, and I'm just delighted to be joined by the chair of this year's meeting, who is also a dear friend, Dr. Andrea Apolo. Dr. Apolo serves within the Center for Cancer Research at the NCI as head of the Bladder Cancer Section, and she is also acting deputy chief of the Genitourinary Malignancies Branch.  Welcome, Andrea, it is so great to have you on the podcast. Dr. Andrea Apolo: Oh, thank you so much for having me. What a great ASCO that we had, it is really exciting, lots of really great data. So I look forward to chatting about it. Dr. Monty Pal: Excellent. And you know, our full disclosures are available in the transcript of this episode in case our listeners want to have a peek.  The theme of this year's GU meeting was "Patient-Centered Care: From Discovery to Delivery." I love that theme. And really, this is one of the most competitive meetings out there, more than 850 abstracts being presented on high-impact science. Andrea, I just wanted to get right into it and dive into what I think we both felt were some of the most exciting abstracts of the meeting.  And the first of those is one that I know is near and dear to your heart, being a bladder cancer expert yourself, and that is the KEYNOTE-B15 study presented by Matt Galsky. Can you give us a flavor for what that study entailed and some of the key results? Dr. Andrea Apolo: Yeah, I think this was kind of the missing study that we have been waiting for since we saw the EV-302 data in metastatic disease in the frontline setting. We wanted to know how well this combination would work in muscle-invasive bladder cancer patients. And we saw half of that puzzle, you can say half of the piece of the puzzle, when we saw the data at ESMO, the EV-303 data in patients that were cisplatin-ineligible. And then now we are getting the full story with patients that are platinum-eligible, cisplatin-eligible, with the EV-304 data. So that study randomized patients to receive chemotherapy, so different than the EV-303 where the patients were randomized just to receive the radical cystectomy. These patients were randomized to receive neoadjuvant EV plus pembro and then adjuvant EV plus pembro versus neoadjuvant gemcitabine and cisplatin with no adjuvant component to the control arm. So I think this is a really, really important study. Dr. Monty Pal: And share with us some of the results because this in my mind is definitely practice-changing. This is one of those studies that I think you walked into the office on Monday and you are like, "Okay, this is what I am doing now," right? Dr. Andrea Apolo: Yeah. So the study was positive. The primary endpoint was event-free survival, and it met the primary endpoint. The secondary endpoint of overall survival was also met. So really, really great results. Consistent with what we saw with EV-303, the median event-free survival was not reached for the EV plus pembro arm, and it was 48 months for the patients receiving gem-cis. And then looking at the 24-month estimated event-free survival, it was 79% for the EV plus pembro and 66% for the chemo, the gem-cis arm. And that was a hazard ratio of 0.5. So that is really exciting. That is the event-free survival. And then the overall survival, the medians were not reached for either arm, but when you look at the 24-month estimated overall survival, it was 87% for the EV plus pembro versus 81% for the gem-cis, and that was a hazard ratio of 0.65. So very positive study.  And then another question that we had was the pathologic CR rate. Very consistent with what we saw with the EV-303, the pathologic response rate was about 56% for the patients that received EV plus pembro and about 32%, 33% for the patients that received gem-cis. So very consistent with the findings that we have been kind of seeing in phase 2 studies, and this is a pT0N0, so that is important. Dr. Monty Pal: So Andrea, you know, I think that the big question in folks' minds is at this point, we see the data from NIAGARA, cis-gem-durva, we have now seen this data. Put it into context for us. Is there a patient in this day and age who maybe shouldn't get IO altogether, who should maybe get the NIAGARA regimen as opposed to EV-pembro in this context? What are your thoughts there? Dr. Andrea Apolo: Now, that is a great question. I would say with this data, it is very enticing to give EV pembro to our patients in the perioperative setting, and for that to be the new standard of care for all patients, regardless of cisplatin eligibility. So similar to what we saw with EV-302 really changing the standard of care in the frontline setting, I think these two studies, the EV-303 and the EV-304, change the standard of care for patients with muscle-invasive bladder cancer in the perioperative setting, and this should be the new standard of care if the patients don't have a restriction to receiving an immunotherapy. Dr. Monty Pal: I totally agree with that assessment. It is great to hear it from the expert's mouth as well. Thanks a lot for that, Andrea.  The next abstract I wanted to tackle is one that is, I would say, near and dear to my heart because I know these folks really well. It is led by the SWOG group, and this is SWOG S1602. The number there for the audience gives you a sense of how long the study has been running for. The 16 prefix means it is something that we kicked off back in 2016. So this study is really 10 years in the making, right? So Rob Svatek presented this data. It is interesting, right, because it addresses this issue of the BCG (Bacille Calmette-Guérin) shortage, right, where we have needed to sort of rely potentially on other alternative sources or regimens and so forth. Tell us about this trial, Andrea. Dr. Andrea Apolo: This is one of my favorite studies. We talked about putting it in the main oral abstracts, but we put it in one of the educational sessions that talked about non-muscle-invasive bladder cancer because we thought that would be the best audience for it. But it doesn't take away from how important this abstract is, and the tremendous effort that went into the study. Almost a thousand patients enrolled. I think 984 were eligible to enroll in this study. So it is a very high enrolling, randomized, cooperative group study in high-grade non-muscle-invasive bladder cancer. And really the study was designed to address two questions. One is the BCG shortage and can we use a different strain, Tokyo versus TICE? And whether there is a priming effect if you gave intradermal BCG to patients with non-muscle-invasive bladder cancer, can that enhance the effect if you gave it a little bit earlier? I think the study is really important, and it met its primary endpoint, which was it is not inferior to TICE. The findings were really terrific in terms of the outcomes. Numerically. When you look at the endpoint, it looked like the Tokyo strain was as good, if not maybe a little bit better, but not statistically significant than the TICE. And then they broke it down by carcinoma in situ, they broke it down by papillary tumors, and the Tokyo strain was non-inferior in both of those instances. But interestingly, the intradermal BCG did not change outcomes. There was really no priming effect, which was really backed up by pre-clinical data that there would be, but there wasn't a priming effect when the intradermal BCG was given in the Tokyo strain. So that was a really, really interesting finding. But a great study, really important outcomes in the field for non-muscle-invasive bladder cancer. Dr. Monty Pal: Totally. And it just seems like we can't get away from BCG, right? You know, as hard as we try, I mean, I appreciate the studies that sort of build on it that are emerging right now, but it seems like BCG at least for the foreseeable future is kind of here to stay, right? Dr. Andrea Apolo: It works. It is one of the most effective treatments we have for non-muscle-invasive bladder cancer. So, you know, I think it is here to stay and, you know, we need to find alternatives in terms of strains so we don't deal with this shortage that we have been dealing with for so many years now. Dr. Monty Pal: Yeah, indeed. Moving on to some of the other highlighted studies from the meeting, you had mentioned the EV-303 data, so we probably don't need to rehash that study design in much detail. But there was also a rapid oral abstract presented by Dr. Ullén that I think is of interest here, right, that really hones in on pathologic outcomes and DFS from that trial. Do you mind just outlining that for our listenership? Dr. Andrea Apolo: This is the KEYNOTE-905, also known as the EV-303 study. This is a follow-up to the EV-303 data looking at the pathologic response rates, looking at the downstaging effect, looking at the surgical margins after treatment with the neoadjuvant EV plus pembro in the 303. Now, remember in the 303, patients got three cycles of neoadjuvant EV plus pembro and then six cycles in the adjuvant setting. A little bit different than the 304, where they got four cycles, which is really kind of the standard in the neoadjuvant setting, and then five cycles in the adjuvant setting. So still a total of nine cycles. But in the 303, the treatment arm had no systemic therapy, so it was just radical cystectomy. And they looked at the negative margins that you get with the EV plus pembro treatment, which was 92.6% versus 79% with patients receiving just the surgery alone. And then the pathologic CR rate, there was more follow-up on that, it was 57% for the patients receiving EV plus pembro, and as we would expect, about 9% for the patients that just went on to surgery alone because you can achieve a pathologic response rate with TURBT alone. Then they looked at the pathologic downstaging, so anything less than a pT2, and that was 66% in the patients that received the EV plus pembro. So very interesting findings, and it is also really just nice to have now the EV-304 data, like I was saying, there were two pieces of it, the cisplatin-eligible and the cisplatin-ineligible, and just to have those contemporary controls are really important. How did the cisplatin-ineligible do versus the cisplatin-eligible patient in terms of the event-free survival and in terms of the overall survival? So I feel like now we have all of this data that we can kind of put together in the perioperative setting and we can really inform our patients a little bit more about their outcomes depending on whether they are cisplatin-eligible or not, which you know cisplatin-ineligible patients often just, they are sicker, they may have obstruction, their tumors may be larger, they just tend to be a more delicate population than the cisplatin-eligible patients. So not surprisingly, you know, we see that in the EV-303 the disease-free survival for the patients is pretty poor. So the disease-free survival that was reported for this follow-up of the specific abstract was 23.6 months for the patients that just got surgery, and it was not reached for the patients that had the EV plus pembro, and that was a hazard ratio of 0.37. Dr. Monty Pal: Excellent, excellent distillation. So Andrea, in the interest of time, I mean, we could probably talk about bladder cancer forever, but I am going to move us on to the subject of kidney cancer. We have two late-breaking abstracts, LITESPARK-011, which looked at lenvatinib and belzutifan versus cabozantinib in the advanced setting, and then we have an adjuvant study, LITESPARK-022, that looked at pembrolizumab with or without belzutifan in the adjuvant setting. Both studies positive. One for progression-free survival, the other for disease-free survival. Both I think making a big dent in how we treat kidney cancer. Can you tell us a little bit about that? Dr. Andrea Apolo: Yeah, we have been waiting for these trials for a long time. So one of the things that we have been talking about at GU ASCO is to have plenary sessions. And if we would have had a plenary session, these two abstracts would have been part of it because they are important data, really big studies where we are trying to improve the outcomes of our patients with kidney cancer. So the first one, the LITESPARK-011, like you said, this is for advanced renal cell carcinoma, clear cell renal cell carcinoma, where we really don't have a standard of care after IO therapy, right? So we give IO-IO, we give VEGF-IO, but we don't really have a good standard of care. We usually give monotherapy TKIs. So the combination of belzutifan and lenvatinib versus what a standard of care is, cabozantinib, is really an important question to ask. And you know, this is a pretty large study, about 750 patients were randomized. And belzutifan plus lenvatinib demonstrated an improvement in progression-free survival and overall survival versus cabozantinib, but not overall survival, at least not yet, is what the authors are saying. So for the progression-free survival, the hazard ratio was 0.7 and it was 14.8 months for the combination, belzutifan plus lenvatinib arm versus cabozantinib, which was 10.7 months. So I think that is significant. And for the overall survival, it did favor the combination again with a hazard ratio of 0.85. The median was 35 months versus 28 months for the monotherapy cabozantinib, but it did not reach statistical significance. And the authors said that this will be further tested at a final analysis, these were the interim results.  And for the overall survival, the overall survival was 53% for the combination versus 40%. This is significant. And the CR rates were lowish for both of them, it was like 5% for the combo and 1% for cabo monotherapy. So I think that the findings are important because we don't have a standard of care. And although there is no survival benefit, there was a trend. So I think this could be considered in patients that are fit, a treatment option for these patients in the later line settings. Dr. Monty Pal: Great points. I mean lots of great discussion around toxicity as well as efficacy. I mean certainly this is a regimen that may not be suitable for every patient in my portfolio, but certainly one to consider.  Now Andrea, let's shift focus to LITESPARK-022, the adjuvant trial that I mentioned previously. So this is again looking at pembrolizumab with or without belzutifan, met the primary endpoint of disease-free survival. What are your impressions there of the data? Dr. Andrea Apolo: Yeah, the data looks great. And this was a really large study, 1,800 patients were randomized, and the study met the primary endpoint of disease-free survival, benefiting the combination of pembro plus belzutifan. And that is really terrific. The medians were not reached for either arm. And in terms of the overall survival results, also the medians were not reached, but the hazard ratio was 0.78 and did not reach a statistical significance. So there was again a statistically significant improvement in disease-free survival for the combination of pembrolizumab plus belzutifan, but not an overall survival benefit.  So I guess, Monty, you know, we can kind of talk about what that means. There was a lot of discussion about belzutifan and some of the side effects, specifically anemia and managing anemia in this setting and requirements for transfusions. Generally, the authors said it was well tolerated, but we know that combination studies do have more toxicity. So it may be a select group of patients again, similar to the advanced setting, where we opt for a combination, possibly until we see more follow-up data in terms of the overall survival. Dr. Monty Pal: I have to agree with you. You know, in my group, we have been talking about a lot of pembrolizumab-based studies that are running right now, some through the NCI, some, you know, our own sort of homegrown investigator-sponsored trials, and you know, I think for the foreseeable future we are comfortable just maintaining pembrolizumab. Things might change if, for instance, we ultimately see a survival advantage emerge, but I just have my own personal doubts around that, that will be interesting.  Okay, so now we are going to move to the last disease category that we are going to cover, which is prostate cancer. So there, we have the long-awaited results from the PEACE-3 study. These are the final OS results from this trial looking at enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer. So Andrea, would love to get your perspectives on this. Dr. Andrea Apolo: Yeah, so this study had been presented before and we had seen positive results for the combination of enzalutamide and radium with some interim overall survival results also showing a benefit. But like you said, these are the final results with a median follow-up of 58 months. So it was really nice to see the final results. And with the combination of enzalutamide and six cycles of radium, it did show an improvement in overall survival with a hazard ratio of 0.76. The median overall survival increased from 32.6 months to 38.2 months with the combination. So that is really great. There was some crossing over of the overall survival curves around 18 months was still seen. And again, there was also an improvement in the rPFS with a hazard ratio of 0.71, and the median rPFS improved from 16.4 to 19 months with the combination. So, you know, we have been awaiting the final results, but we kind of knew a lot about the benefits of the combination. And it is something that is kind of slowly trickling into the community in terms of adapting it and using it. There is more buzz now about it and I think these overall survival results will hopefully shift the community into incorporating the combination in these patients. Dr. Monty Pal: Brilliant. So well said. I mean, Andrea, congratulations on a terrific meeting. You have really done it again. Incredible, incredible output from this year's ASCO GU. I just want to thank you for joining us on the program today. Dr. Andrea Apolo: Oh, thank you so much for having me, Monty. It was really a joy to work with the ASCO team and with all the investigators and the Education Committee and the Scientific Committee. Everyone was really outstanding. So to me it was an honor to be part of this meeting, and I am so happy that it was so successful and really presented some amazing data that I think will be practice-changing to our patients. Dr. Monty Pal: Oh, thanks a ton. And also a huge thanks to our listeners. If you enjoyed the content of today's podcast, please don't forget to like and subscribe to our channel wherever you listen to podcasts. Thanks so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Andrea Apolo @apolo_andrea  Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Andrea Apolo: No disclosures to report.

This archived episode of the Texas Predator Hunting Podcast comes from a live Instagram Q&A session.Wade answers two straight hours of listener questions covering:• 6 ARC gas system tuning• 22 ARC vs 22 Creedmoor• Adjustable gas blocks & bleed-off mode• Suppressor setups (flow-through vs traditional)• AR buffer weights & tuning philosophy• Barrel life (22-250, 22 Creed, 6 ARC)• Proof Research barrels• Bolt & BCG myths• Load development basics• Cleaning procedures for bolt guns & ARs• Titanium vs stainless suppressors• Trigger recommendations• Factory ammo performance insightsThis one goes deep into real-world rifle setup, tuning for cold weather, and maximizing AR platform performance for predator hunting.If you're running 6 ARC, 22 ARC, 22 Creed, or tuning a suppressed AR, this episode is packed.allymunitions.com

La inteligencia artificial prometía un salto inmediato en productividad. Sin embargo, los datos globales muestran otra realidad: el impacto existe, pero no es automático ni homogéneo. Pilotos que no escalan, proyectos que se abandonan y organizaciones que no logran convertir eficiencia individual en valor de negocio marcan el pulso de esta etapa.En este episodio conversamos con Julián Herman, Managing Director y socio de BCG, para entender por qué muchas empresas están atravesando la “paradoja de la IA”: tecnología disponible, resultados limitados.Entre otros aspectos hablamos de:La diferencia entre productividad individual y organizacionalPor qué tantas empresas no logran impacto fuerte con IAEl error de implementar IA sin rediseñar procesosCómo medir productividad antes y después de incorporar IA

Did you know that combining Bacillus Calmette-Guérin (BCG) with immunotherapy significantly improves outcomes in high-risk bladder cancer? Credit available for this activity expires: 2/24/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/immunotherapy-non-muscle-invasive-bladder-cancer-expert-2026a10005af?ecd=bdc_podcast_libsyn_mscpedu

Blood detected in Bob Schreiber's urine led to a diagnosis of Stage IV bladder cancer.  This came after a cystoscopy, in which a tube is inserted into his urethra, taking a picture of the bladder.  Twice without success, Bob hoped BCG treatment would address the cancer by instilling a set of chemicals inside the bladder to strengthen the immune system.  As a result, he had to get his bladder removed.  It was replaced with a neobladder, which was made from his small intestine.  His recovery took close to a year, he has to deal with incontinence at night, but would his overall health is about 80 percent of what it was pre-diagnosis.   In 2015, Bob's cancer journey began when a lab tech detected microscopic drops of blood in his urine.  This got the attention of a urologist, who immediately suspected cancer and called for a cystoscopy of Bob's bladder.  The doctor wanted to make sure there was cancer and that if there was cancer, to make sure it had not spread beyond the muscle of Bob's bladder.  Thankfully, the cancer had not spread, but the photos from the cystoscopy confirmed Bob Schreiber had Stage IV bladder cancer.   Bob was told in terms of treatment, the gold standard is the removal of his bladder, but he learned of a potential remedy called BCG instillation.  Under this procedure, chemicals would be instilled into the bladder to strengthen its immune and defeat the cancer.  Bob and his wife preferred to go this route, but the operation was unsuccessful.   They switched hospitals and made a case for a second attempt at BCG instillation, claiming kidney damage that occurred on the first attempt may have compromised the first attempt's effective.  A new care team went ahead with the second BCG instillation, but it, too, was unsuccessful.  This left Bob with no other option than to have his cancerous bladder removed.   Although he could have chosen treatment that would have left him with a bag to collect his urine, he instead went with a neobladder.  That's a replacement bladder made from his small intestine.  The difficult and dangerous took eight hours. A day after its conclusion, Bob got up and walked around the hospital floor.  And he walked and he walked and he walked.  By the time he was done, Bob said he had walked about a mile and a half!  Hospital staff had done a better job of bouncing back from this particular surgery than any patient they had ever had.  Whereas many patients remained hospitalized after this procedure for weeks, Bob went back home just four days after the surgery was done.   Bob Schreiber said recovery was slow, but he made progress.  He said then, and now, he is able to remain continent during the day but does have incontinence issues at night and has to make trips to the bathroom every three or four hours.   Bob says his health is approximately 80 percent of what it was prior to his diagnosis, but he is extremely grateful to be able to chase after his small grandchildren.   Additional Resources:   Support Group:   The Bladder cancer Advocacy Network: https://www.bcan.org    

What makes a leadership team truly high performing, and why does it matter for the entire organization? Judith Wallenstein, CEO Advisory Global Lead of BCG, and Khadija Ben Hammada, Chief People Officer of Merck KGaA, Darmstadt, Germany, explore this topic and more. They share how CEOs can build executive teams grounded in trust, purpose, and psychological safety. When the top team clicks, the whole company moves faster and with more clarity.Learn more: https://lnk.to/so-what-general-show32Learn More:Judith Wallenstein, Managing Director & Senior Partner, Global Lead, CEO Advisoryhttps://www.bcg.com/about/people/experts/judith-wallensteinKhadija Ben Hammada, Member of the Executive Board and Chief People Officer for Merck KGaA, Darmstadt, Germanyhttps://www.emdgroup.com/en/company/management/executive-board/khadija-ben-hammada.htmlSubscribe to BCG's YouTube channel: https://goo.gl/hsFsVTVisit us at https://www.bcg.comChapters(00:00) Intro(00:17) How do you build a high-performing leadership team?(01:36) What makes a team work?(02:12) What does a high-performing team feel like?(03:45) How much of team success depends on the CEO's behavior and decisions?(05:55) When hiring, what are you looking for — what's the secret sauce?(08:47) What should the CEO–Chief People Officer relationship look like?(09:50) What did you learn as chief of staff that you apply on an executive team?(11:42) How do team members to elevate collective performance?(13:01) How should leadership adapt in an era of uncertainty?(16:35) How do you keep a team successful when key people move on?(19:27) What's steps should leaders take now to create a top-performing team?(21:03) OutroThis podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Send a textIf you're a non-MBA advanced degree (PhD, MD, JD, PharmD, etc.), this is your roadmap into consulting.Bridge Programs are one of the fastest – and most misunderstood – paths into firms like McKinsey, BCG, Bain, L.E.K., ClearView, Oliver Wyman, and more. With 2026 deadlines upon us, timing matters.In this episode, we break down exactly how advanced degree candidates can win.You'll walk away with:A clear understanding of how bridge programs work – and how they fast-track you to interviews and offersA step-by-step game plan to position your academic background for consultingThe confidence to navigate resumes, networking, digital assessments, and case interviewsA concrete action plan you can start executing todayThese programs are competitive and high-signal. If you're serious about breaking into consulting this year, this is where you start.Resources:Bridge Program Details: See 2026 eligibility and key deadlines by firmConsult with Katie: Explore whether a Management Consulted program is the right fit for you (15-min call)Black Belt: Structured coaching to win your consulting offerBook with Ish: Get personalized bridge strategy and case prep guidanceJoin the last-ever Strategy Sprint (March 7-14)Build consulting experience, boost your resume, and make a real impact on this 1-week consulting project (the last-ever project) MBB Undergrad Timelines Are Moving UpApplication deadlines are the earliest we've ever seen; join Black Belt for a structured, MBB-led prep plan + coaching + resume editsConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

Recent analysis from Goldman Sachs indicates that $700 billion in AI investment during 2025 resulted in no measurable U.S. GDP growth, with most AI equipment imports negating domestic benefits and 80% of surveyed firms reporting no productivity or employment improvements. This pattern suggests that AI-related spending has primarily shifted margins from enterprise IT budgets to a small number of infrastructure vendors rather than delivering distributed value. Internal concerns are rising, with 90% of IT leaders questioning AI's return on investment, and 80% citing fragmented data as a primary challenge to measuring outcomes. Further context reveals that agentic AI initiatives face operational headwinds: Gartner expects 40% of such projects to be cancelled by 2027, and S&P Global found nearly half are abandoned before production, most often due to inadequate planning and data foundations. Margin erosion is widespread, attributed to AI implementation costs, and attempts to scale AI agents into production remain limited by inference costs and insufficient infrastructure. Despite increased adoption efforts, sustainable value delivery from AI platforms remains elusive for most organizations. Enterprise AI access is becoming increasingly concentrated. OpenAI's partnership with consulting firms such as BCG, McKinsey, Accenture, and Capgemini consolidates control of the enterprise distribution layer, narrowing competitive opportunities for smaller providers. Meanwhile, Amazon's 13-hour AWS outage, linked to the misconfiguration of an internal AI tool, underscores the liability ambiguity in agentic systems—where vendors may attribute autonomous actions to user error, complicating risk assignment. Additional updates from vendors such as Anthropic, Cloudflare, and New Relic address incremental technical capabilities, with a distinct focus on cost, operational governance, and policy enforcement. The prevailing themes for MSPs and IT leaders are increased scrutiny of AI value, heightened exposure to cost and accountability risk, and the emergence of managed service opportunities around data governance, cost instrumentation, and liability management. With enterprise market channels consolidating and risk shifting toward service providers, integrating robust contractual definitions for autonomy, incident attribution, and financial boundaries is essential to limit harm and clarify responsibility before incidents occur. Four things to know today 00:00 Goldman: $700B AI Spend Delivered Near-Zero U.S. GDP Growth in 2025 03:49 OpenAI Enlists BCG, McKinsey, Accenture to Distribute Enterprise AI Agents 06:44 Report: Amazon's Own Engineers Prefer Claude Over Its Mandated Internal Tools 08:56 AI Inference Costs Are Falling — But Governance Gaps Are Growing This is the Business of Tech.    Supported by: CometBackup  Small Biz Thoughts Community   

Boston Consulting Group, (BCG), renowned for innovative strategic solutions and growth strategies in business, advises that, “revisiting your mission is essential to ensure that an organization's core purpose, strategy, and daily actions remain aligned as it evolves, preventing it from becoming outdated or losing focus. Regularly reviewing the mission keeps stakeholders engaged, ensures relevance in a changing market, and guides strategic decisions.” As with any healthy business or organizations, from time-to-time local churches must revisit the core of their mission and vision. Not just because prestigious business consulting firms commend it, but because GOD'S Word does! Proverbs 29:18 states: “Where there is no vision, the people perish…” While I am deeply aware that a local church is so much more than a “business endeavor", we as GOD's people, need to keep the unique vision and mission HE has given us at Riverbluff continually before us. We need to challenge one another with it, and we need to use it as a standard by which all of our ministries constantly recalibrate. I hope you'll make plans now to join us for this message as we press deeper into GOD's call for us to be HIS Church together! Pastor Joe Still

Stephen Grootes speaks to Peter Tollman, Senior Partner Emeritus at Boston Consulting Group and founding leader of BCG’s CEO Advisory Practice, about what truly drives CEO success. Drawing on years of advising global chief executives, Tollman challenges the myth of the “superstar” CEO who can thrive in any context, arguing instead that performance is deeply situational shaped by timing, mandate, and environment. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 See omnystudio.com/listener for privacy information.

Several firms like MIT's Nanda Lab and BCG have released reports claiming the vast majority of companies have delivered little to no measurable business value from their investments in AI. But what if they're wrong? Join us as we speak to LCP's very own Ed Bonnett, Head of AI, to find out how companies can deliver real efficiencies and productivity gains from AI. We talk about the common early stumbling blocks companies make when they first use AI, what the future of companies could look like as they struggle with to keep up with the fast pace of change in this landscape, and top tips for anyone looking to better adopt AI into their systems. Mentioned in this episode: our cutting-edge AI tool designed to revolutionise content accessibility: https://www.lcp.com/en/our-technology/transpose

Listen to Full Audio at https://podcasts.apple.com/us/podcast/ai-business-and-development-daily-news-rundown/id1684415169?i=1000751248515

We're living in the "centaur era" of AI and if you're not combining human judgment with AI tools, you're already falling behind. In this episode, Zack Cohen and the Bitcoin Policy Hour team break down the BCG study proving that AI-augmented workers crush both pure humans and blind AI users, then pivot to Secretary Rubio's landmark Munich Security Conference speech signaling the end of the postwar order with Europe. Plus, the hosts analyze Bitcoin ETF flows, whale selling pressure, and why a federal judge just ruled your AI chat logs aren't privileged.

In this episode of Eye on AI, Craig Smith speaks with Amanda Luther, Senior Partner at Boston Consulting Group and global lead of BCG's AI Transformation practice, about what their latest 1,500-company AI study reveals about the widening gap between AI leaders and laggards. Only 5% of companies are truly "future-built" with AI embedded across their core business functions. These firms are seeing measurable gains in revenue growth, EBIT margins, and shareholder returns. Meanwhile, 60% of organizations are either experimenting or struggling to extract real value. Amanda breaks down how BCG measures AI maturity across 41 capabilities, how AI impact flows through the P&L, and why leading companies invest twice as much in AI as their competitors. She explains where AI is actually creating value today, from sales and marketing to procurement and retail operations, and why most of that value comes from core business functions, not back-office automation. The conversation also explores the rise of agentic systems, why many early agent deployments fail, and what it really takes to redesign workflows around AI. Amanda shares practical advice for companies stuck in experimentation mode, how to prioritize the right use cases, and why training and change management matter more than chasing the perfect vendor. If you want to understand how AI is reshaping competitive advantage in enterprise organizations, this episode provides a data-backed look at what separates the leaders from everyone else.   Stay Updated: Craig Smith on X: https://x.com/craigssEye on A.I. on X: https://x.com/EyeOn_AI   (00:00) The AI Value Gap (01:17) Inside BCG's 1,500-Company AI Study (04:14) What "Future-Built" Companies Do Differently (09:30) How AI Impact Is Measured on the P&L (12:57) Why AI Leaders Invest 2X More (14:16) Where AI Is Driving Real Cost Reduction (16:20) Agentic AI: Hype vs Reality (20:13) Where Agents Actually Create Value (24:22) Tech vs Talent: Where the Money Goes (26:58) Will AI Laggards Slowly Disappear? (31:58) Why Adoption Is Accelerating Now (40:07) How to Start: Amanda's Advice to AI Laggards  

Enterprise XR hasn't disappeared, it has quietly moved into places where it saves time, reduces errors and changes how people work every day. On this episode of the AI XR Podcast, Charlie Fink and Rony Abovitz talk with Boston Consulting Group partner Kristi Woolsey, who leads BCG's immersive practice, about how XR plus AI is already being used for training, maintenance, onboarding, retail and architecture inside some of the world's most conservative organizations.Kristi shares a Swiss Rail project where field technicians wear lightweight AR glasses that recognize who they are and which train car they are standing in front of, pull the correct procedures from internal systems and use AI to turn thick manuals into simple task checklists.She explains how this leads to double-digit efficiency gains for both experienced and new workers, and how a small behavior design choice – automatic logging for headset users versus manual end-of-shift paperwork for everyone else – helped overcome skepticism on the front line. Drawing on her background as a physical-space architect, she also describes how VR and rapidly improving 3D tools are changing the way companies design stores, offices and buildings before anything physical is built.AI XR News you should know, Charlie and Rony cover Anthropic's massive new funding round and ethics turbulence, Chinese generative video tools like Seed Dance 2 and Kling that put TV-quality visuals in reach of “garage Spielbergs,” and Meta's reported seven million Ray-Ban and Oakley AI smart glasses sold – early signals of where wearable AI and XR are really headed.Key Moments01:03 – Anthropic's huge raise and what the ethics departure might signal05:08 – Seed Dance 2 and Kling showcase a new level of generative video08:35 – Meta's seven million smart glasses and the reality behind that number12:10 – Why wearable AI may be the real “last mile” of turning us into cyborgs15:28 – Inside the early metaverse tours Kristi and Rony built for enterprises20:27 – How BCG's VR onboarding keeps new hires engaged months before day one23:30 – Swiss Rail's AR and AI maintenance assistant and what it actually does on site27:05 – Designing XR systems that give value to both the business and frontline workers30:29 – Using VR as a lab for retail and workplace behavioral strategy33:06 – How AI-generated 3D models point toward “build every space digitally first”This episode shows how “metaverse” ideas have turned into practical tools: XR plus AI is cutting training times, improving maintenance quality and letting companies experiment with spaces before they exist. Kristi's examples make it clear that the real action is in careful workflow design, not flashy avatars.This episode is brought to you by Zappar, creators of Mattercraft, the leading visual development environment for building immersive 3D web experiences for mobile, headsets and desktop. https://mattercraft.io/Mattercraft combines the power of a game engine with the flexibility of the web and now includes an AI assistant that helps you design, code and debug in real time, right in your browser. To explore what's possible with AI-powered XR on the web, start building smarter with Mattercraft from Zappar.Listen to “Enterprise XR Meets AI: How Smart Glasses, Digital Twins and Holodecks Are Quietly Changing Work – Kristi Woolsey” on the AI XR Podcast and follow the show for new episodes every week.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Laura Konitzer is a founder building AI-powered decision tools for fashion and retail teams. She also works with brands on AI strategy and practical adoption. Previously, she spent nearly a decade at BCG advising global fashion and consumer brands.In this episode, Svenja Hofe interviews Laura, who brings nearly a decade of experience advising fashion and luxury brands. Laura shares her transition from consulting into fashion tech and AI, and they discuss how AI is reshaping the industry and the challenges around data readiness.

Private Equity ist nicht gleich Private Equity. Zwischen Midcap- und Largecap-Investoren liegen oft nicht nur unterschiedliche Dealgrößen, sondern völlig unterschiedliche Denkweisen, Prozesse und Hebel zur Wertschöpfung. Mein Gast heute ist Robin Mürer, Co-Managing Partner bei FSN Capital. Mit ihm spreche ich nicht nur über seinen Weg vom Physikstudium und Unternehmertum über Largecap-PE bei Apax bis zum Midcap-Fokus bei FSN – sondern auch darüber, warum Value Creation und KI die Zukunft des Private-Equity-Geschäfts prägen werden.Wir beleuchten in dieser Episode:wie man als Physiker ins PE kommt,wie der skandinavische PE-Markt tickt,wie sich Mid- und Largecap-PE unterscheiden,wie die aktuelle Marktlage im Private Equity aussieht,was Robin für die Zukunft des Private-Equity-Markts erwartet,und vieles mehr... Viel Spaß beim Hören!***Timestamps:(00:00:00) Intro(00:02:34) Der Weg von Physik zu Private Equity(00:05:42) Erste Schritte in der Unternehmenswelt(00:09:32) Einstieg ins PE(00:11:45) Erfahrungen bei BCG und Apax(00:16:27) Zeit bei Apax und Finzanzkrise(00:20:15) Bekannte Deals bei Apax(00:23:34) Wechsel zu FSN Capital(00:27:08) Kultur und Teamaufbau bei FSN Capital(00:28:13) Fonds, Investmentstrategien und Marktanalysen(00:29:37) Private Equity in Skandinavien(00:31:50) Branchenfokus(00:33:34) Marktentwicklung und Investitionsmöglichkeiten(00:35:32) Herausforderungen im Midcap Segment(00:37:17) Targets im Largecap Segment(00:41:00) Tempo im Midcap(00:47:13) Vendor & Financial Due Diligence(00:54:09) Prozessdauer im Midcap(00:56:57) Dry Powder vs. fehlende Käufer(01:00:00) Investitionstiming(01:08:29) Hebel im Largecap***Alle Links zur Folge:Kai Hesselmann auf LinkedIn: https://www.linkedin.com/in/kai-hesselmann-dealcircle/CLOSE THE DEAL auf LinkedIn: https://www.linkedin.com/company/closethedeal-podcastRobin Mürer auf LinkedIn: https://www.linkedin.com/in/robin-muerer-a15240/FSN Capital auf LinkedIn: https://www.linkedin.com/company/fsn-capital/Website CLOSE THE DEAL: https://dealcircle.com/ClosetheDeal/***AMBER und DUB.de sind die Plattformen für sichere Unternehmensnachfolgen. Schaut vorbei, wenn ihr euer Unternehmen schnell, sicher und kostenfrei zum Verkauf inserieren wollt oder als Käufer auf der Suche nach passenden Deals seid:www.amber.dealswww.dub.de***Du bist M&A-Berater im Small- oder Midcap-Segment und suchst einen Überblick über alle relevanten Deals? Jetzt schnell den

Europa muss dringend wirtschaftlich enger zusammenrücken – das ist das Ergebnis einer Studie der Unternehmensberatung Boston Consulting Group (BCG), in der 850 Top-Manager und 6400 Bürgerinnen und Bürger befragt wurden. Angesichts der US-Zollpolitik und der Konkurrenz aus China sehe eine überwiegende Mehrheit der Antwortenden großen Handlungsdruck, sagte Matthias Tauber, der das Europageschäft von BCG leitet, im Capital Wirtschaftspodcast: „Mehr als 90 Prozent der Top-Manager sind überzeugt, dass Europa seine wirtschaftlichen Interessen dringend schützen muss.“ Wichtigster Auslöser sei der Tag gewesen, an dem US-Präsident Donald Trump seine Zollsätze für einzelne Staaten verkündete. Gefordert werde „nicht notwendigerweise Protektionismus“, wie er aktuell von den USA ausgeht, sondern vor allem das Prinzip „europäischer Champions“ in einzelnen Branchen, sagte Tauber. Zudem forderten die Manager eine stärkere Kooperation in Finanzfragen wie beispielsweise mit der europäischen Bankenunion. Eine große Mehrheit der Befragten sei der Ansicht, „dass mehr Europa Teil der Antwort ist und nicht weniger Europa“. Eine Produktion von RTL+ Podcast.Host: Nils Kreimeier.Redaktion: Lucile Gagnière.Produktion: Andolin Sonnen. +++Weitere Infos zu unseren Werbepartnern finden Sie hier: https://linktr.ee/diestundenull +++60 Tage lang kostenlos Capital+ lesen - Zugriff auf alle digitalen Artikel, Inhalte aus dem Heft und das ePaper. Unter Capital.de/plus-gratis Dieser Podcast wird vermarktet von Julep Media: sales@julep.de

The global energy transition is growing in complexity with shifting economics, soaring electricity demand, and competing national priorities. Maurice Berns and Asheesh Sastry from BCG's Center for Energy Impact lay out how leaders can keep up by focusing on the economics, creating strategies for individual markets, and staying ahead of policy shifts.Learn More:Maurice Berns, Chair, BCG Center for Energy Impact https://www.bcg.com/about/people/experts/maurice-bernsAsheesh Sastry, Managing Director & Senior Partner https://www.bcg.com/about/people/experts/asheesh-sastryThe Energy Transition's Next Chapter https://www.bcg.com/publications/2025/global-energy-landscape-next-chapterBCG Center for Energy Impact https://www.bcg.com/industries/energy/center-for-energy-impact/defaultAbout the Energy Transition https://www.bcg.com/industries/energy/energy-transitionThis podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Synopsis: At the heart of JPM 2026's biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could reshape medicine. Fred traces his journey from medical school in Brazil to consulting at BCG, venture capital, and ultimately founding multiple companies—sharing why following curiosity, not rigid career ladders, shaped his path. Fred dives deep into the bottlenecks holding back traditional CAR-T therapies—manufacturing complexity, cost, hospitalization, and toxicity—and explains how Artiva's off-the-shelf NK-cell platform aims to change the paradigm. The discussion explores why rheumatoid arthritis became Artiva's lead indication, how immune “resets” could redefine autoimmune care, and what's ahead in 2026 as the company prepares registrational trials and expands its basket studies across lupus, myositis, scleroderma, and more. The episode closes with rapid-fire takes on AI in drug development, China's accelerating biotech engine, rare disease trial models, and the strategic principles founders should follow when choosing indications and building durable platforms. Biography: Fred Aslan, M.D., has a 20-year track record as an executive and investor in the life sciences industry. He was most recently President and CBO at Vividion Therapeutics, where he was responsible for business development, finance, alliance and project management, and operations. Dr. Aslan had the opportunity to lead Vividion's Series B financing and $135M-upfront collaboration with Roche. Prior to Vividion, Dr. Aslan had a 12-year affiliation with Venrock. Initially he was an investor from 2006 to 2013, when he cofounded and served as a board member of Receptos Pharmaceuticals (acquired by Celgene for more than $7 billion). Dr. Aslan led Venrock's investment in Zeltiq (acquired by Allergan for more than $2 billion) and was involved in the early formation of Fate Therapeutics. Subsequently as an entrepreneur from 2013 to 2018, he was CEO of Adavium Medical, a Brazilian medical device company, which he grew from zero to 350 employees, sales of over US$40 million, and fully integrated R&D, manufacturing, and commercial capabilities. Prior to Venrock, Dr. Aslan was Director of Business Development and Head of Investor Relations for CuraGen, a Nasdaq-listed oncology-focused biotech company. Prior to CuraGen, he was a consultant at Boston Consulting Group (BCG). Dr. Aslan holds a B.S. in biology from Duke University, an M.D. from Yale School of Medicine, and an MBA from Harvard Business School.

La storia di Amplifon ha radici davvero profonde, piantate tra le macerie di un'Italia ferita, quella del dopoguerra. Charles Holland, dopo la guerra, si stabilisce in Italia e, da uno scantinato in Via Cerva a Milano, crea un'azienda che oggi è una multinazionale presente in tutti i 5 continenti. Ma come ha fatto quella filosofia così "soft", basata sull'empatia, a diventare il motore di un'innovazione che dura da 75 anni? Amplifon è la seconda impresa che raccontiamo in questo nuovo spin off di Actually, realizzato in collaborazione con BCG, in cui ripercorriamo le storia delle aziende italiane che hanno fatto la Storia industriale del nostro Paese. Learn more about your ad choices. Visit megaphone.fm/adchoices

If you like variety, this is your episode.  Malukas and perms.  F1 engine controversy and what should happen.  Freedom 250 and Justin demanding a suite.   Justin's bizzare Indycar dreams.  Scotty Mac's intentions. BCG experience.  It is all here in a big way.  @hiroindycar

Send us a textIn this Strategy Simplified episode, you'll hear a McKinsey case interview example built around a real-world investment decision.The client is a public university considering whether to add an inter-collegiate football program. Led by former McKinsey Senior Associate Jali Packer, this case challenges a candidate to assess costs, revenues, and strategic tradeoffs for a football program at a 10,000-student university in the Southern U.S.If you want to practice structuring an open-ended question like “Is this a good idea?” – and see how McKinsey interviewers test thinking along the way – this case is for you.Work with Jali:View Jali's 1:1 coaching calendarJoin the Black Belt case prep program for personalized coaching with Jali and a prep strategy tailored to your goals and timelineConnect with Jali on LinkedInAdditional Resources:Book a free 15-minute call with Katie to explore coaching optionsWatch more McKinsey, BCG, and Bain case interview demos on YouTubeConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

2030 will be here before you know it with a new world for food. .Ozan Ozaskinli is a Food Futurist and manufacturing strategist who’s asking questions about the future of what we eat and how we’ll produce it. He’s led transformation projects across 17 industries, spent 20+ years at firms like BCG, and now runs Value Gene, where he helps U.S. manufacturers modernize before tech disruption makes them obsolete. Originally from Europe, a big part of Ozan’s POV is how far ahead Europe is when it comes to food systems and what the U.S. can (and should) borrow before it’s too late. He talks about food in 2050, factory floors in 2025, and how leaders need to embrace change now.

197: What if the most underrated role in leadership is actually the one that makes everything run? In this episode of Executive Office Insights, Joe Davis (Senior Advisor, former Managing Director & Senior Partner, and North America Regional Chair Emeritus, BCG) and Mary Kate Steincke (Administrative Services Manager, former Senior EA) unpack what real executive support looks like when it evolves into true partnership. You'll hear how high-performing leaders and EAs build trust, decision rights, and a shared operating rhythm. The best support isn't "task help," but a strategic advantage that protects focus, energy, and outcomes. They also explore the leadership mindset behind great partnerships: mentorship without strings attached, honest feedback, and the human side of high standards—the kind of principles that shape culture and careers. Finally, they look ahead at how AI and modern tools are changing admin work, what will (and won't) be automated, and what skills will matter most for the next generation of executive support professionals. What to expect in this conversation: - Executive Assistant → Executive Partner: What makes the shift happen? - The leadership behaviors that create trust (and the ones that break it) - Career paths, titles, and what "progression" can really look like - AI, automation, and the future of the EA/admin function About Joe Davis Joe is a Senior Advisor at Boston Consulting Group (BCG) and a former Managing Director & Senior Partner, where he worked for 37 years. He founded and is Chair of BCG's Center for Inclusion and Equity (CIE). He co-founded and later led BCG's Washington, D.C. office, and founded BCG's U.S. Public Sector Practice. Joe served as Chair of BCG North America, responsible for operations in the United States, Canada, and Mexico. As Regional Chair, he advanced inclusion, diversity, and racial equity by launching BCG's Racial Equity Task Force, publishing BCG's first public U.S. DEI Report, and founding BCG's CIE (where he currently serves as Chair). His client work focused on the Consumer/Retail, Public Sector, and Organization Practices, primarily on fundamental transformations, change, and organizational effectiveness. Outside of BCG, Joe serves as Chair of the Whitman College Board of Trustees and holds an MBA from Harvard Business School. Joe and his spouse Sarah have four children and eight grandchildren. He published The Generous Leader: 7 Ways to Give of Yourself for Everyone's Gain in April 2024. About Mary Kate Steincke Mary Kate is an Administrative Services Manager at BCG with more than eight years of experience supporting senior leadership and driving administrative excellence across the NAMR region. Since joining BCG in 2017, she has worked in Administrative Services—starting as an Administrative Assistant and later becoming an Executive Assistant and Senior Executive Assistant (plus Specialist-level roles)—while supporting Joe Davis, BCG's North America Regional Chair. She managed complex, high-stakes calendars, communications, leadership meeting rhythms, and onsite support for major regional events and executive visits. Her work ranged from strategic prep for leadership engagements to orchestrating multi-layered client meetings, regional town halls, cohort forums, and cross-office initiatives, with high precision and ownership. She's recognized for creating order, clarity, and calm, and supported large-scale operational efforts including COVID-19 response coordination, regional communications, digital signage programs, and leadership forums, while mentoring new administrative staff and shaping a cohesive cross-office experience. She built training initiatives for the NAMR Administrative Services cohort, including a new series on supporting BCG's Managing Directors and Partners that is now a Regional offering. Colleagues praise her grace, empathy, and extraordinary service orientation—calling her "Disneyland personified," a "BCG Rockstar," and someone who makes high-pressure situations "feel like a summer breeze." Today, as Administrative Services Manager for the NYC and Brooklyn teams, she continues to elevate administrative operations, strengthen team culture, and enable leaders and staff to work at their highest potential. Outside of BCG, Mary Kate enjoys time with friends and family, especially in Atlantic Beach, and earned a BA in Communications and Marketing from Loyola University Maryland. - Diana Brandl on LinkedIn: https://www.linkedin.com/in/diana-brandl/ - Executive Office Insights Newsletter: https://the-socialista-projects.com/#newsletter - Podcast on Spotify: https://open.spotify.com/show/3qBSDjTfYOG2x6qos7dKkS - Podcast on Apple Podcast: https://podcasts.apple.com/de/podcast/the-future-assistant/id1493106661 The Executive Office Insights Spotify Playlist: https://open.spotify.com/playlist/3QH8HL8oWIC0HzHWvb5KLd Guest Picks: Mary Kate Steincke: Light On by Maggie Rogers Joe Davis: Buy Me a Rose by Kenny Rogers

In our final take on ESMO 2025, we talk about Genitourinary Cancers. This was a dense area with numerous trials. Today we explore distimiab vedotin in those with advanced bladder cancer, the role of combining lutetium with an ARPI in advanced prostate cancer, whether de-escalation of docetaxel in high volume prostate cancer was just as efficacious as the regular six cycles, immunotherpay plus bCG in non-muscle invasive bladder cancer, adjuvant durvalumab in renal cell caricnoma and the perioperaive role of enforumab vedotin for muscle invasive bladder cancer.We're out of breath just listing off these trials, and if this hasn't gotten you excited, then probably nothing will! See you next week, where we interview our spectacular guest Professor Jenny Seligmann, who will bring you up to date on Michael's favourite topic, colorectal cancers!Studies:IMvigor011 (NCT04660344)KEYNOTE 905/EV-303 (NCT03924895)POTOMAC (NCT03528694)ARASAFE (NCT02799602)RC48-C016 (NCT05302284)PSMAddition (NCT04720157)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners, Pfizer and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

AI risk is moving faster than most organizations can write, let alone implement new policies.By the time a “Responsible AI” policy is approved, Generative AI has shifted the goalposts and “Agentic AI” is already raising the stakes for compliance professionals.In this episode our host Hanjo Seibert sits down with Reid Blackman, author of The Ethical Nightmare Challenge. This book unpacks a more innovative, scalable approach to AI governance: one that's designed to be rapidly implementable, adaptable, and pilotable, without turning governance into a bottleneck.You'll also hear why his approach is meant to work across levels (i.e. project, department, enterprise), and why cross-functional collaboration is non-negotiable when AI touches everything.We're kicking off a brand new series of BCG on Compliance with our 2026 opener and we're excited to bring you more stories from the ever-evolving world of compliance.On BCG on Compliance, we dive deep into the extraordinary minds driving change—from ethics champions to risk innovators, bringing rich insights from global players shaping the future of compliance, in a dynamic and compact episode.Whether you're a seasoned pro or new to the field, BCG on Compliance is your quick, comprehensive guide. Connect with us at bcgoncompliance@bcg.com. New episodes are released monthly. Listen wherever you get your podcasts.Episode LinksReid Blackman LinkedInThe Ethical Nightmare Challenge (book)Hanjo Seibert LinkedInBCG WebsiteBCG LinkedInApple: https://podcasts.apple.com/ca/podcast/bcg-on-compliance/id1716794444

Join several BCG senior partners as they share their insights from their time on the ground at the World Economic Forum Annual Meeting in Davos. BCG invites you to an exclusive look at the forces shaping the CEO agenda in 2026. BCG's Judith Wallenstein, Aparna Bharadwaj, and Vlad Lukic discuss what they learned from their personal conversations with CEOs and global leaders at Davos. They share practical guidance for organizations preparing for the year ahead in AI, geopolitics, and other areas. Chapters Learn more: BCG at Davos, https://www.bcg.com/about/partner-ecosystem/world-economic-forum/davos BCG's CEO Agenda, https://www.bcg.com/executives/ceo-agenda Judith Wallenstein, Global Leader, CEO Advisory https://www.bcg.com/about/people/experts/judith-wallenstein Aparna Bharadwaj, Global Leader, Global Advantage Practice https://www.bcg.com/about/people/experts/aparna-bharadwaj Vlad Lukic, Global Leader, Tech and Digital Advantage https://www.bcg.com/about/people/experts/vladimir-lukic This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

In this special edition of This Week in Global Development, recorded at Davos, we explore a fundamental shift in the development landscape: the move from funding gaps to impact-driven results. As global economic constraints and fragmented cooperation redefine the sector, the conversation is no longer just about how much money can be mobilized, but how leadership and innovation can scale impact in a complex world. Devex President and Editor-in-Chief Raj Kumar sits down with Jim Larson, managing director and senior partner at BCG, to discuss the “impact pivot” of 2026. Larson outlines how successful players are moving beyond traditional aid by integrating generative artificial intelligence as core infrastructure and restructuring their "capital stacks" through blended finance and private sector partnerships. From the necessity of market-driven efficiency to the rise of inclusive, localized coalitions, Larson shares case studies on how technology and innovative finance are moving the needle on global health. They also examine the specific characteristics defining successful development leaders in this new era of market imperatives. To hear more about the evolution of the development toolkit, listen to this conversation with Jim Larson on This Week in Global Development. Sign up to the Devex Newswire and our other newsletters: https://www.devex.com/account/newsletters

François Bazini, CMO of Suntory Beverage & Food Europe is one of the most thoughtful brand CMOs in global FMCGFrançois shares a rare, inside view of what it really means to be a brand steward in organisations like Danone, BCG, PepsiCo and Suntory. From resisting short-term zig-zagging, to building brands that can withstand private label pressure, this conversation goes deep on the realities of modern brand leadership. We explore why marketers must act as brand CEOs, how tension with CFOs can be productive rather than problematic, and why targeting older audiences is one of the most under-exploited growth opportunities in marketing today. François also unpacks the Ribena turnaround, Schweppes' response to Fever-Tree, and why most advertising testing is misunderstood. This is a wide-ranging, honest discussion about judgment, evidence, culture, and the long game in brand building.Topics include: Brand stewardship vs short-termism, marketing ROI, working with finance, global vs local marketing roles, age targeting myths, private label competition, creative testing, and why some brands endure while others drift.03:25 – Career path: from Danone to consulting and global brand roles04:55 – What BCG teaches marketers about being fact-based07:00 – Brand stewardship and avoiding strategic zig-zagging09:30 – Timeless vs timely brand decisions11:00 – Marketing ROI beyond short-term sales12:30 – Marketers as brand CEOs13:45 – Working with CFOs and productive tension16:00 – Global vs local marketing roles20:00 – Ribena: brand decline and recovery22:30 – Going back to a brand's peak moment26:00 – The myth of always targeting youth29:00 – Schweppes, Fever-Tree and category disruption31:45 – Targeting over-45s unapologetically34:00 – Media thresholds and focus over fragmentation35:45 – Moving beyond marketing mix modelling38:15 – The limits of advertising testing41:00 – When great ads fail tests but succeed commercially42:20 – Competing with private label43:00 – DAQV: desirability, affordability, quality, visibility Hosted on Acast. See acast.com/privacy for more information.

Today's episode of the Punk CX podcast is with Deborah Honig, Chief Customer Officer at Samsung UK & Ireland. Deborah joins me today to talk about shifting Samsung's UK & Ireland business from innovation-led storytelling to service-led experiences, the servitization process, how they are building AI into their products, how they are building trust with customers to fuel adoption, how customers are reacting to that and what's next for Samsung and their move towards service-led experiences. Given that Deborah is deeply immersed in this space, we finish off with the trends and things she expects to see/emerge in the coming 12 months, her best advice for brands wanting to build standout customer experiences, her Punk CX brand, and her very own good news story. This interview follows on from my recent interview – Automate problems, not just symptoms – Interview with Nick Clark of BCG – and is number 570 in the series of interviews with authors and business leaders who are doing great things, providing valuable insights, helping businesses innovate and delivering great service and experience to both their customers and their employees.

In Episode 34, Dr. Aly-Khan Lalani and Dr. Christopher Wallis sit down with Dr. Fleshner to explore how an academic surgeon transitioned from traditional clinical and research roles into medical entrepreneurship. From tackling Canada's BCG shortage to co-founding a pharmaceutical company that sold for over a billion dollars, Dr. Fleshner walks through how he has built and scaled successful businesses in medicine.This episode delivers a masterclass on growing your impact beyond the clinic without losing your connection to medicine.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by AbbVie, Astellas, Ipsen, and Merck.

CEOs must pursue growth transformation with the same rigor that they bring when they tackle costs. Tuukka Seppä, BCG's global chair of transformation, explains why CEOs need bold targets, smart incentives, and relentless follow-through to scale effectively. He unpacks the common misconceptions that hold companies back, the impact of a chief transformation officer, and why this is the moment to shift from reacting to rebuilding. Listen on podcast platforms: https://lnk.to/so-what-general-show12 Learn More: Tuukka Seppa: https://www.bcg.com/about/people/experts/tuukka-seppa BCG's Latest Thinking on Business Transformation: https://www.bcg.com/capabilities/business-transformation/insights CEO's Guide to Growth in 2026 article: https://www.bcg.com/publications/2026/the-ceos-guide-to-growth-seizing-opportunity BCG at Davos 2026: https://www.bcg.com/about/partner-ecosystem/world-economic-forum/davos Chapters: 00:00 Introduction 00:28–00:55 What's Your “So What” on Growth? 00:55–01:50 If Growth Is a Strategic Choice, What Does It Take to Succeed? 01:50–03:16 Why Do Some Companies Grow During Extreme Volatility? 03:16–04:13 What Does Structured Growth Leadership Look Like in Practice? 04:13–05:12 Can Too Much Discipline Limit Growth in a Volatile World? 05:12–06:03 How Do You Build Flexibility and Adaptability into Growth? 06:03–07:36 Is It Obvious Where Growth Should Come From? How Do Leaders Decide What Good Growth Is? 07:36–10:20 Why Do Two-Thirds of Companies Miss Growth Targets? 10:20–11:05 What Does “Growing from a Strong Base” Mean? 11:05–12:35 How Do You Measure Growth Without Killing It Too Early? 12:35–13:55 How Important Is a Chief Transformation Officer? 13:55–14:37 What Buffers Matter for Growth — and Why Now? 14:37–16:06 What's the Typical Timeline for a Growth Transformation? 16:06–17:54 What Unlocks the Shift from Efficiency to Growth? 17:54–19:48 What Role Can AI Play in Accelerating Growth? 19:48–20:41 When Is the Right Time to Start a Growth Program? 20:41–21:33 The ‘Now What' 21:21–21:33 Outro This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

MY NEWSLETTER - https://nikolas-newsletter-241a64.beehiiv.com/subscribeJoin me, Nik (https://x.com/CoFoundersNik), as I interview Sean O'Dowd (https://x.com/SeanODowd). In this episode, I sit down with Sean to discuss his transition from consulting at BCG to launching Scholastic Capital, a real estate fund that targets homes in high-end school districts. We explore how he used the Catalant platform to scale his independent consulting income to over $500,000 a year by acting as a versatile "athlete" for private equity firms. Sean shares the gutsy move of leaving that high salary for zero income to build a professional leadership team and why he views consulting as the perfect "business training wheels".We also dive into his "underrated" use of Twitter as a powerful fundraising engine and a way to recruit elite vendors and investors. This is a must-watch for anyone interested in operations, asset management, and the logistics of a portfolio roll-up. Enjoy the conversation!Questions This Episode Answers:1. How can an independent consultant scale their earnings to over $500,000 a year?2. What is the specific investment thesis behind buying rental homes in elite school districts?3. How can Twitter be utilized to find investors, vendors, and legal counsel for a fund?4. What are the "business training wheels" learned in consulting that prepare you for entrepreneurship?5. How do you successfully win real estate deals while being the lowest bidder?__________________________Love it or hate it, I'd love your feedback.Please fill out this brief survey with your opinion or email me at nik@cofounders.com with your thoughts.__________________________MY NEWSLETTER: https://nikolas-newsletter-241a64.beehiiv.com/subscribeSpotify: https://tinyurl.com/5avyu98yApple: https://tinyurl.com/bdxbr284YouTube: https://tinyurl.com/nikonomicsYT__________________________This week we covered:00:00 Highlights00:40 Introduction to the Real Estate Fund01:08 From Consulting to Real Estate01:48 The Consulting Journey02:33 Breaking into Entrepreneurship03:49 The Catalan Experience04:30 Financial Success and Lifestyle Changes12:40 Starting the Real Estate Fund17:40 Understanding the Fund Structure18:23 Management Fees and Team Building19:11 GP LP Model Explained19:39 Preferred Returns and Fund Models20:10 Hiring and Operational Costs23:23 Growth Strategy and Future Plans25:45 Acquisition Strategy and Market Focus28:23 Twitter as a Fundraising Tool31:46 Investor Relations and Transparency32:55 Current Performance and Market Tactics

Happy New Year! This is the time of year when people make big changes. So, I'm bringing back my conversation with the co-author of Tomorrowmind. It's a fascinating book and especially relevant at this time of the year. Dr. Gabriella Rosen Kellerman writes that that career trajectories used to be like steamships (full steam ahead), and then they became more like sailboats (lots of tacking), but now we're swirling in whitewater. So how can we stay afloat? How can we flourish? “When you're kayaking in the whitewater. It's hard to get a sense of what could be around the bend, but if you know if what's coming up is a sudden cascade or versus another, you know, set of gentle bumps, or maybe it's a calmer space in the river, it can give you a great advantage.”On this episode of CRAFTED., we focus on PRISM, the five key skill groups that Gabriella says can help you be more successful: Prospection, Resilience, Innovation and creativity, Social support by way of rapid rapport, and Mattering and meaning. Gabriella was until recently the Chief Product Officer at BetterUp, a platform that helps organizations and people level up through a mixture of human and AI coaching. She originally appeared on the show in a two-part episode. Part one is includes more on the tomorrowmind skills and her career path; in part two, she describes how BetterUp builds products and innovated under her leadership. And stay tuned as we employ our own tomorrowminds here at CRAFTED... there are some big changes to the show, including a new name, coming this month!---Featured voices:Dr. Gabriella Rosen Kellerman, Partner at BCG, former CPO of BetterUp, and co-author, with Martin Seligman, of Tomorrowmind Me (Dan Blumberg) — I'm the host of CRAFTED. and the founder of Modern Product Minds. HMU if you want to build something great! I love building from zero to one.---And if you please…Share with a friend! Word of mouth is by far the most powerful way for podcasts to growSubscribe to the CRAFTED. newsletter at crafted.fmShare your feedback! I'm experimenting with new episode formats and would love your honest feedback on this and other episodes. Email me: dan@modernproductminds.com or DM me on LinkedInSponsor the show? I'm actively speaking to potential sponsors for 2026 episodes. Drop me a line and let's talk.Get psyched!… There are some big updates to this show coming soon!

The CPG Guys are joined by Chris Riegel CEO of STRATACACHE  with retail solutions that allow them to be partners in creating an in-store evolution, fitting into retail existing ecosystem by connecting different technologies to truly drive a frictionless store visit. This episode is sponsored by STRATACACHEFind Chris Riegel on LinkedIn here: https://www.linkedin.com/in/chris-riegel-6931a28/Find STRATACACHE on LinkedIn here: https://www.linkedin.com/company/stratacache/Find STRATACACHE online here: https://www.stratacache.com/en/Chris answers these questions:You are hosting a full day focused on retail media inside the physical store—a deliberate choice given how much attention off-site and digital retail media still get. What convinced you that the store deserved its own moment right now? Is it fair to say the industry is moving from speculation to proof? What triggered that shift?We'll have voices from BCG, McKinsey, EMARKETER, and Solomon Partners in the room. When consultants, analysts, and investors all start telling a similar story, what does that signal to you?One of the themes we'll explore during the day is the idea that the traditional funnel has collapsed and influence now happens closer to the moment of purchase. Why is the store uniquely resilient in that new influence model?Why do you think shoppers still trust in-store media more than online media? Is that trust something retailers can scale without breaking it?We'll hear during the day that agentic AI is compressing margins in digital retail media. Help connect the dots for our audience—why does that dynamic actually elevate the strategic value of physical stores?If AI makes digital media more efficient but less differentiated, does the store become one of the few environments where context still matters more than targeting?Why is that shift so foundational to unlocking real retail media scale in stores?We'll have IAB and measurement leaders talking about standards. From your perspective, how important is measurement alignment to making in-store media credible to brands and CFOs?What separates retailers who are moving from pilots to platforms from those who are still stuck in experimentation?We'll also explore how the store is becoming a fully expressive media environment—not just screens, but experience. For brands listening, what does “store-native creative” really demand of them?What outdated thinking do you hope gets challenged during this event? Is the biggest barrier today technology, standards, or internal politics?Looking ahead to 2026, what will define success for retailers who fully embrace in-store media versus those who don't?CPG Guys Website: http://CPGguys.comFMCG Guys Website: http://FMCGguys.comSheCOMMERCE Website: https://shecommercepodcast.com/Rhea Raj's Website: http://rhearaj.comLara Raj in Katseye: https://www.katseye.world/DISCLAIMER: The content in this podcast episode is provided for general informational purposes only. By listening to our episode, you understand that no information contained in thi CPGGUYS LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual's use of, reference to, or inability to use this podcast or the information we presented in this podcast.

In this classic episode of Logistics with Purpose®, hosts Enrique Alvarez and Kristi Porter welcome Joe Davis to the show, Managing Director and Senior Partner at Boston Consulting Group (BCG), and author of "The Generous Leader." Listen in as Davis shares insights from his extensive career, emphasizing the importance of feedback, vulnerability, and inclusivity in leadership. He recounts his experiences at Proctor and Gamble, BCG, and his role in bringing the 50th Super Bowl to San Francisco with a focus on community impact. Davis also discusses his book, which outlines seven traits of generous leadership, advocating for a leadership style that fosters growth and potential in others. Tune in to learn more about the value of listening, authenticity, and small acts of recognition in effective leadership.Additional Links & Resources:Check out The Generous Leader: https://www.amazon.com/Generous-Leader-Ways-Yourself-Everyones/dp/1523006617Learn more about Boston Consulting Group: https://www.bcg.com/Connect with Joe: www.linkedin.com/in/joedavis131Learn more about Logistics with Purpose®: https://supplychainnow.com/program/logistics-with-purposeLearn more about Vector Global Logistics: https://vectorgl.com/Subscribe to Logistics with Purpose®: https://logistics-with-purpose.captivate.fm/listenThis episode was hosted by Enrique Alvarez and Kristi Porter and produced by Amanda Luton. For additional information, please visit our dedicated show page at: https://supplychainnow.com/generous-leadership-action-insights-feedback-vulnerability-inclusivity-lwp113

Rich Lesser, BCG's global chair, and Martin Reeves, chairman of the BCG Henderson Institute, reflect on the shocks and surprises that shaped the first half of the decade and what they reveal about the future. They explore the traits leaders need today: building trust, staying geopolitically aware, and adopting AI in a people-centered way.Learn More:Rich Lesser: https://on.bcg.com/4lZrWlaMartin Reeves: https://on.bcg.com/4lXaAVXWinning in the 20s: https://on.bcg.com/4lpe1ooWinning the '20s: A Leadership Agenda for the Next Decade: https://on.bcg.com/40iscDsThis podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Double Tap Episode 441 This episode of Double Tap is brought to you by: Blue Alpha, Midwest Industries, Gideon Optics, Primary Arms, Die Free Co., and Mitchell Defense   Welcome to Double Tap, episode 441! Your hosts tonight are Jeremy Pozderac, Aaron Krieger, Nick Lynch, and me Shawn Herrin, welcome to the show! Text Dear WLS or Reviews +1 743 500 2171 - Dear WLS ThreeRaccoons InnaTrenchCoat - What programs do Shawn, Nick and Savage use for 3D modeling? Are they subscription based or free? I would like to dive into 3D modeling but don't really want to pay a subscription. A one-time fee would be okay i suppose. Tuul Steele - "I was thinking Hard the other day about that long, cylindrical reciprocating part of an Assault Railer - 15 and it got me curious (bi-curious) about steel selection for a BCG. YES, I know all steel is not created equally Jeremy, but in the case of the BCG which does the cast recommend and which is just more expensive for no reason. Not talking coatings, although you can add that to the pot, I am mainly referring to the materials; Carpenter 158 aka "The Thing", 9310 aka "The Beverly Hills BCG", or S7 Tool Steel aka "The Audi Tool". Love the show and the cast. You guys are keeping me topside on long days. Keep up the good work. Also just buy Aaron a huffy with a baseball card in the spokes and call it a day. Toss in a bottle of Malort for the basket on the handle bars. #WLSisLife #shootstraight" Plow Guy Dave - What do you think will be the cool, new trend at SHOT Show this year? Do you think that there will be an influx of NFA stuff like SBR's, SBS's and suppressors since the One Big Beautiful Bill will be active? I know you guys don't go to SHOT anymore, but what would you like to see come out? John B - So I was listening to the AR-15 podcast and Dauly keeps saying you need to buy mags in “generational wealth” volume. What is it that you guys think is the appropriate number of mags to have for your rifle and pistol? Do I really need to have 10 mags minimum? Gus Gus - Hello people and Aaron, What one thing do you each think we do or use or teach in the firearms space that we will one day look back on and say “wow, I can't believe we let that happen” (besides letting Aaron speak). Could be anything from gear to training to lawfare practices. For myself, I think open emitter red dots on concealed carry guns will be looked at as weird and genX level fuddery and anyone who uses one will always feel like explaining it away like Jeremy does with iron sights. Thanks guys and Aaron Unfit for Human Consumption - What software would you recommend for tracking a gun collection? I have (only) a few dozen guns, and have been using "NMCollector" since about 2005, and it meets my needs. It is now $15/year which is very reasonable, and a "lifetime" activation is less than 85-bucks. A quick search on the interwebs for alternatives reveals "ArmoryBook" which is $200/yr for up to 50 records, and "GunTrack" which is $100/yr for up to 100 records; both are way over budget for my needs. Are there other softwares I'm not aware of that you'd recommend? I don't keep pictures generally, and all I really need to track is make, model, caliber, description, year & country of manufacture, source, cost, appraised value, etc for insurance records and for my wife to cash in on this "401(G)uns" fund when I'm gone (hopefully not for several decades). Or should I just create an Excel spreadsheet? Sunshine Shooter - Forced Reset triggers seem to be a commercially available thing now, but I'm having trouble keeping track of what is out there. What forced reset triggers/super safeties do you recommend I look into getting for a poor man's MP5 I'm planning on putting together? Matthew P - Just bought a 5 inch VFM-9 from Foxtrot Mike. What accessories would you add to this if you are going to keep it as a backpack gun? Suppressor? Flip up sights and/or red dot/prism? sling? anything else?   The winner of this week's swag pack is Gus Gus! To win your own, go to welikeshooting.com/dashboard and submit a question!   Gun Industry News Cops Pick New Echelon Guns Henderson PD picked Springfield Armory's Echelon 9mm pistols (full-size 4.5F and compact 4.0C) as new duty guns after tough tests. Special modular grips fit all hand sizes, ambidextrous controls, optics-ready, 20-round mags. Every officer passed quals first try—first time ever. Boosts gun community's cred for civilian carry. Available now. New S&W .360 Buckhammer Rifle Out Now Smith & Wesson Model 1854 lever-action rifle now in .360 Buckhammer caliber for straight-wall hunting states. Mixes classic lever feel with modern Picatinny rail, M-LOK slots, 20-inch barrel. Hits medium/large game with low recoil. MSRP $1399. Available now. POF-USA Wins Big Rifle Deal for Asia POF-USA wins contract to supply Renegade rifles in .300 Blackout with 8-inch barrels to Asian client. Special: E² dual-extraction, roller cam pin, heat sink nut for reliability and heat control in suppressed ops. Boosts POF's global sales. Not for civilian sale. Germany Picks CZ P-10 C as New Gun Germany's army picked the CZ P-10C OR FDE pistol as its new P13 service gun, replacing the old HK USP from 1994. It's a 9mm striker-fired model with 15-round mag, 4-inch barrel, 26 oz weight, optic-ready slide in flat dark earth finish—beats Glock and Arex in competition. Huge win boosts CZ's rep; big order expected from Czech plant. Not yet in production for delivery. Colt Wins M4A1 and Suppressor Deal Colt got a $12.93M contract for M4A1 carbines, suppressors, and flash hiders for Israel via US Foreign Military Sales. Special: Includes suppressors, now common for stealth. Boosts Colt's gun community rep as key military supplier. Product not available now. Ruger Wins Patent for Double Stack .22LR Magazines Ruger patented a double-stack .22LR magazine for 22/45 pistols. It uses single-feed that splits to two columns, rotating rims sideways to center bullets—special for rimfire without bulky design. Fits current frames as aftermarket, no background check needed. Boosts gun community with higher capacity. Broader for .22 WMR, .30-30, 7.62x54R. Not available yet. New HK VP9A1 X: Perfect Size and Power Heckler & Koch launched VP9A1 X pistol, blending compact 4-inch slide from K model with full-size F frame for 17-round capacity. Fills gap between compact and full-size with A1 upgrades like better grip and trigger. MSRP $1,049 or $1,399 optics-ready. Available now. Gun fans get factory crossover size matching original VP9 but improved.   Before we let you go - Join Gun Owners of America   Tell your friends about the show and get backstage access by joining the Gun Cult at theguncult.com.   No matter how tough your battle is today, we want you here fight with us tomorrow. Don't struggle in silence, you can contact the suicide prevention line by dialing 988 from your phone. Remember - Always prefer Dangerous Freedom over peaceful slavery. We'll see you next time!   Nick - @busbuiltsystems | Bus Built Systems Jeremy - @ret_actual | Rivers Edge Tactical Aaron - @machinegun_moses Savage - @savage1r Shawn - @dangerousfreedomyt | @camorado.cam | Camorado

On this week's episode of The Origins Podcast, I ended up in a place I genuinely never expected to go: the humble “like” button. When the idea first landed in my inbox, my reaction was basically, why on Earth would anyone write a whole book about that? Then I spoke with Martin Reeves, and I discovered that the history of this tiny icon is a surprisingly rich window into innovation, entrepreneurship, human psychology, and the modern attention economy.Martin is a senior figure at BCG's Henderson Institute, but what made the conversation especially fun for me is that he is not a consultant who wandered into science. He has a background in science, and then wandered into the world of strategy, technology, and ideas, and he approaches the “like” button the way I wish more people approached our digital world: with curiosity, skepticism, and a willingness to follow evidence across disciplines.The central irony, of course, is that the “like” button began as an almost laughably small, practical solution. In the story Martin and his coauthor reconstructs, it is often less about a single inventor than about a messy ecosystem of micro innovations, technical constraints, and cultural accidents. Yet those small choices compound. The result is that something as simple as a handful of code became a universal signal that helped shape social media, transformed advertising, and created feedback loops that are now baked into the infrastructure of daily life.We also dig into why it works so well on us. The mechanisms are not mysterious in the abstract, they are biological and social, but the scale is unprecedented. Approval and recognition are ancient. Industrialized approval is new. And once you start thinking that way, you notice how these same feedback dynamics are spreading into new domains, including the tools we now use to interact with AI.This conversation surprised me, and I suspect it will surprise you too. Indeed, if you are like me, and wondered why the like-button is worth discussing, you will be surprised to learn how much of the modern world is quietly organized around it. You can listen on any podcast platform, watch on YouTube, or view ad free on Substack. And if you are tempted at the end, well, you may even find yourself clicking the very thing we spend the episode dissecting.You can listen on any podcast platform, watch on YouTube, or view ad free on Substack. And if you are tempted at the end, well, you may even find yourself clicking the very thing we spend the episode dissecting.As always, an ad-free video version of this podcast is also available to paid Critical Mass subscribers. Your subscriptions support the non-profit Origins Project Foundation, which produces the podcast. The audio version is available free on the Critical Mass site and on all podcast sites, and the video version will also be available on the Origins Project YouTube. Get full access to Critical Mass at lawrencekrauss.substack.com/subscribe

Many companies have a blind spot when it comes to serving women. In fields from health care to financial services, they often treat women just like men—even though their needs are very different. BCG's Alex Friedman and Trish Stroman share tangible steps leaders can take today to better serve women—who are responsible for up to 80% of spending. Organizations that are best positioned won't guess what women want—they'll co-create with them and design for real needs. Learn More: Alex Friedman: https://on.bcg.com/3XW4lry Trish Stroman: https://on.bcg.com/3KSkJWU Closing the Menopause Care Gap: The Next Frontier in Women's Health https://on.bcg.com/4oWSkNo BCG's Latest Thinking on the Healthcare Industry: https://on.bcg.com/3KXXCdH BCG's Innovate Her: https://on.bcg.com/3KSqiVs Chapters: 00:00-00:57 Introduction 00:58-02:26 Why don't businesses successfully target and serve women? 02:27-03:30 Why is women's health still underinvested in? 03:31-05:04 Why has momentum shifted? 05:05-06:06 How big of an economic opportunity is this? 06:07-07:06 Where are the most immediate areas businesses can create value? 07:07-08:30 How can you scan your business for opportunities? 08:31-09:21 What do leaders say are the biggest opportunities and stumbling blocks? 09:22-11:50 Upcoming innovations that could solve problems for female consumers 11:51-12:58 What sectors have the most to gain from targeting female consuemrs? 12:59-14:13 What businesses are excelling? 14:14-16:03 Is there enough investment in this space? 16:04-17:52 What's the productivity and talent cost when women aren't supported? 17:53-19:38 How to persuade a board that this is worth investing resources in 19:39-21:04 The ‘Now What' 21:05-21:15 Outro This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

#MentorshipPodcast #FinanceCareer #ConsultingJourney #BCG #Vision2030 #CareerGrowth #InternationalBusiness #leadershiplessons Claudio shares his incredible global journey — from starting in European finance and insurance, to working on Vision 2030 transformation projects in Saudi Arabia, and later joining BCG in management consulting. His story is a masterclass in adaptability, mentorship, and lifelong learning across borders.

Send us a textWhere do McKinsey, Bain, and BCG consultants go after they leave?We analyzed 1,600+ MBB exits to build a live map of where opportunity is compounding — and which skills the market is paying a premium for.In this episode, Namaan breaks down the 2025 MBB Exit Opportunity Analysis and the 5 trends shaping where consultants go next.You'll learn:The top industries hiring ex-MBB in 2025Why most exits go private (not public)Which roles accelerate the move into operating leadershipHow to choose: product, capital, or CEO proximityDownload the full report for free here.Additional Resources:Download free 2025 MBB Exit Opportunity Analysis reportReach out to Namaan: namaan@managementconsulted.comPartner Links:Learn more about NordStellar's Threat Exposure Management Program; unlock 10% off with code SIMPLIFIED-10Connect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

Help us celebrate our very own Georgie Frost, who earned the Bronze Lovie Award for Best Podcast Host thanks to her outstanding work on The So What from BCG!Georgie was also a finalist for the People's Lovie Award for Best Podcast Host. The Lovie Awards are the European cousin of the Webby Awards, celebrating the best of the best across the continent. If you'd like to send a warm note, a congratulatory message, or simply an email full of emoji confetti, please send an email to thesowhat@bcg.com.Congratulations to Georgie and thank you all for making the podcast a success!This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

How do you guide a workforce through the fastest shift in technology most of us have seen in our careers? That question shaped my conversation with David Martin from BCG, who works at the intersection of talent, culture, and AI. He joined me from New York, with Amelia listening in, and quickly painted a clear picture of what is really happening inside global enterprises right now. We started with the widening split between AI fluent teams and those stuck in endless pilots. David explained why the organizations getting results are the ones doing fewer things with far greater ambition. Many others scatter energy across small use cases, save minutes instead of hours, and never reach a scale where value becomes visible. Training surfaced early as one of the biggest gaps. Not surface level workshops, but the deeper hands-on learning that helps people change how they work. David described why frontline teams lag behind, why engineers still miss major capabilities, and how leadership behaviour dramatically affects adoption. Curiosity and communication play a bigger role than most expect. We explored the move from isolated AI experiments to real workflow transformation. David shared examples from engineering, customer service, and operations where companies are finally seeing measurable results. He also explained why agents remain underused, with hesitation, data quality, and unfamiliarity still slowing progress. Shadow AI added another layer, with half of workers already using tools outside corporate systems. The conversation returned often to people. David outlined BCG's 10-20-70 rule, showing why technology is never the main bottleneck. Culture, roles, and process make or break outcomes. Leaders who provide clarity and a sense of direction see faster adoption. Those who remain hesitant create uncertainty that spreads across teams almost instantly. As we looked toward 2026, David shared cautious optimism. He sees huge potential in areas like healthcare and sustainability, along with a wave of workflow redesign that will reshape daily work. His own learning habits are simple, from podcasts to regular reading, and driven by a desire to set a strong example for his children as they grow into a world shaped by AI. If you want a grounded view of where AI is genuinely delivering change, this conversation offers rare clarity. What resonates with you most from David's perspective, and how will you approach your own learning in the year ahead? I would love to hear your thoughts.   Tech Talks Daily is Sponsored By Denodo. To learn more, visit denodo.com

In this episode, mining and commodities expert Mikhail Zeldovich joins host Constantin Kogan for a rare deep dive into the real engines of the global economy — critical minerals, geopolitics, and the future of resource investing.From BCG to Rio Tinto to negotiating in Beijing and analyzing assets in remote mining camps, Mikhail brings nearly two decades of on-the-ground experience across metals, energy transition, and global supply chains.He breaks down:⚒️ How he “accidentally” entered mining at BCG — and why he never left